Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:KNSANASDAQ:OPTNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$35.50+2.3%$30.54$23.42▼$62.58$2.06B0.73659,781 shs549,418 shsKNSAKiniksa Pharmaceuticals International$27.93-0.1%$25.81$17.38▼$30.69$2.04B0.06517,873 shs487,811 shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1826,649 shsN/AVCELVericel$41.78+0.7%$41.43$37.39▼$63.00$2.10B1.33416,216 shs404,506 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+2.90%+17.67%+13.42%-16.59%KNSAKiniksa Pharmaceuticals International0.00%+0.72%+4.61%+19.56%+53.46%OPTOpthea0.00%0.00%0.00%0.00%+82.35%VCELVericel0.00%-1.65%-4.00%-9.68%-3.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals3.8362 of 5 stars3.41.00.04.21.10.81.9KNSAKiniksa Pharmaceuticals International3.2028 of 5 stars3.53.00.00.02.63.30.6OPTOpthea0.6069 of 5 stars2.10.00.00.00.80.80.6VCELVericel2.3114 of 5 stars3.51.00.00.01.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6065.07% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8038.92% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideVCELVericel 3.00Buy$61.1446.34% UpsideCurrent Analyst Ratings BreakdownLatest OPT, VCEL, KNSA, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M56.33N/AN/A$27.02 per share1.31KNSAKiniksa Pharmaceuticals International$423.24M4.82N/AN/A$6.60 per share4.23OPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09VCELVericel$237.22M8.87$0.31 per share133.70$5.92 per share7.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.16N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A111.72N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)VCELVericel$10.36M$0.031,393.1394.95N/A1.25%1.09%0.73%7/30/2025 (Estimated)Latest OPT, VCEL, KNSA, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43OPTOptheaN/A1.57N/AVCELVericelN/A5.014.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AKNSAKiniksa Pharmaceuticals International53.95%OPTOpthea55.95%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%KNSAKiniksa Pharmaceuticals International53.48%OPTOpthea3.20%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableOPTOpthea8153.91 million148.99 millionNot OptionableVCELVericel30050.34 million47.73 millionOptionableOPT, VCEL, KNSA, and AGIO HeadlinesRecent News About These CompaniesStephens Reaffirms Overweight Rating for Vericel (NASDAQ:VCEL)June 18 at 2:03 AM | americanbankingnews.comConestoga Capital Advisors LLC Sells 7,830 Shares of Vericel Co. (NASDAQ:VCEL)June 17 at 5:20 AM | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?June 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Overweight" Rating from StephensJune 16, 2025 | marketbeat.comVericel Corporation: Moving From Sell To NeutralJune 12, 2025 | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11, 2025 | morningstar.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10, 2025 | globenewswire.comGAMMA Investing LLC Acquires 127,028 Shares of Vericel Co. (NASDAQ:VCEL)June 10, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Receives $61.14 Consensus PT from AnalystsJune 10, 2025 | americanbankingnews.comCongress Asset Management Co. Purchases 22,579 Shares of Vericel Co. (NASDAQ:VCEL)June 7, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Given Average Recommendation of "Buy" by AnalystsJune 7, 2025 | marketbeat.comPortside Wealth Group LLC Buys New Position in Vericel Co. (NASDAQ:VCEL)June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 16,466 Shares of Vericel Co. (NASDAQ:VCEL)June 3, 2025 | marketbeat.comWellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVericel's (VCEL) Overweight Rating Reiterated at StephensMay 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AGMay 24, 2025 | marketbeat.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial MarketsMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comLazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?OPT, VCEL, KNSA, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$35.50 +0.81 (+2.33%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$35.49 -0.01 (-0.01%) As of 06/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Kiniksa Pharmaceuticals International NASDAQ:KNSA$27.93 -0.02 (-0.07%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$27.94 +0.01 (+0.04%) As of 06/18/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 06/18/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Vericel NASDAQ:VCEL$41.78 +0.28 (+0.67%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$41.78 -0.01 (-0.01%) As of 06/18/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
